Supernus Announces First Quarter 2020 Financial Results

First quarter total revenue of $95.0 million, an 11% increase over 2019

First quarter net product sales of $92.5 million, an 11% increase over 2019

First quarter operating earnings of $29.0 million, a 14% increase over 2019

On track for launch of SPN-812 at the end of 2020, pending FDA approval. PDUFA date of November 8, 2020 for review of NDA

Acquisition of CNS portfolio of US WorldMeds expands and strengthens neurology portfolio with established marketed products and late-stage pipeline. Expected to close in second quarter 2020

Partnership with Navitor Pharmaceuticals expands psychiatry portfolio with Phase II program for potential treatment of depression

ROCKVILLE, Md., May 05, 2020 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today reported financial results for the first quarter of 2020 and associated Company developments

Commercial Update

First quarter 2020 product prescriptions for Trokendi XR^® and Oxtellar XR^®, as reported by IQVIA, totaled 203,404, a 2% increase over first quarter 2019.

Source: IQVIA

First quarter 2020 net product sales were $92.5 million, an increase of 11% over $83.1 million in the first quarter of 2019. As previously disclosed, wholesalers, distributors, and pharmacies decreased their inventory levels of the Company’s products in the first quarter of 2019. The Company estimates that this caused net product sales in the first quarter of 2019 to be approximately $10 million lower had inventory levels remained constant, thus favorably impacting year over year net product sales growth in the first quarter of 2020.